Qureight, an end-to-end imaging company focused on lung and heart disease clinical trials, raised $20 million in Series B financing led by Molten Ventures, with participation from existing investors Hargreave Hale AIM VCT, XTX Ventures, Guinness Ventures, Meltwind, and Ascension. The capital will fund expansion of Qureight’s 3D deep learning imaging portfolio through a new AI imaging laboratory, extending its models into asthma, pulmonary hypertension, bronchiectasis, and drug-induced lung toxicity alongside its existing lung fibrosis work. Dr Inga Deakin of Molten Ventures and Anna Salim of Hargreave Hale are joining Qureight’s Board of Directors, as the company, led by co-founder and CEO Dr Muhunthan Thillai, positions itself in a global lung and heart clinical trials market expected to reach $27.5 billion by 2030. The funding will also allow Qureight to scale its commercial team and develop its AI-powered quantitative imaging analytics platform, which includes global imaging CRO services, proprietary AI Lung image biomarkers, and data science products including synthetic control arms.